Related Experiment Video

Updated: Apr 15, 2026

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
06:38

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies

Published on: April 12, 2017

14.4K

Immune Escape in Renal Cell Carcinoma: Latest Research and Treatment Strategies

Kaixiang Huang1, Ke Chen1

  • 1Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430100, China.

International Journal of Molecular Sciences
|April 14, 2026
PubMed

Insights

Kidney cancer's immune escape mechanisms hinder effective treatment. This review details these mechanisms and new strategies to overcome immune evasion in renal cell carcinoma.

Area of Science:

  • Oncology
  • Immunology
  • Urology

Background:

  • Renal cancer is a prevalent urinary system malignancy.
  • Immune escape mechanisms in kidney cancer impede the immune system's ability to eliminate cancer cells, promoting tumor progression and metastasis.
  • Current immunotherapies for kidney cancer face challenges with high recurrence rates, drug resistance, and severe side effects.

Purpose of the Study:

  • To systematically review the latest mechanisms of immune escape within the renal cancer immune microenvironment.
  • To summarize novel treatment strategies targeting these identified immune escape mechanisms.

Main Methods:

  • Literature review of recent research on renal cancer immunology and immunotherapy.
  • Systematic summarization of identified immune escape pathways and corresponding therapeutic approaches.

Main Results:

  • Key immune escape mechanisms identified include abnormal histocompatibility complex (MHC) expression, secretion of immunosuppressive factors, programmed death ligand-1 (PD-L1) dysregulation, recruitment of immunosuppressive cells, and VHL gene deletion.
  • Emerging treatment strategies are being developed to counteract these specific immune evasion tactics.

Conclusions:

  • Understanding these renal cancer immune escape mechanisms is crucial for developing more effective immunotherapies.
  • This review provides a foundation for future research into novel strategies to overcome immune evasion in renal cell carcinoma.
Keywords:
MHC-1PD-L1VHLimmune escaperenal cancer

More Related Videos

The Use of Reverse Phase Protein Arrays RPPA to Explore Protein Expression Variation within Individual Renal Cell Cancers12:22

The Use of Reverse Phase Protein Arrays RPPA to Explore Protein Expression Variation within Individual Renal Cell Cancers

Published on: January 22, 2013

34.3K
Modeling Spontaneous Metastatic Renal Cell Carcinoma mRCC in Mice Following Nephrectomy11:27

Modeling Spontaneous Metastatic Renal Cell Carcinoma mRCC in Mice Following Nephrectomy

Published on: April 29, 2014

17.3K

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.2K
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

1.5K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.4K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.5K
Metastasis02:30

Metastasis

Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
7.0K